The new results, presented at the Association for Research in Vision and Ophthalmology (ARVO) 2024 meeting in Seattle, USA, suggest that the therapy achieved improvements in vision and may slow down the progression of RP, according to eyeDNA, a newly formed subsidiary of France’s Coave Therapeutics.
Approximately 100,000 people in the US and an estimated 2 million people worldwide suffer from RP, a condition that results in progressive damage to light-detecting cells in the retina and is the leading cause of inheritable blindness.
